Citations

Clear

92 citation(s) found for "Johnson, Sarah".

Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy
Desai, Aakash , Kosari, Farhad , Disselhorst, Maria , Yin, Jun , Agahi, Alireza , Peikert, Tobias, Udell, Julia , Johnson, Sarah H. , Smadbeck, James B. , Karagouga, Giannoula, McCune, Alexa, Schaefer-Klein, Janet, Cheville, John C. , Vasmatzis, George , Baas, Paul, Desai, Aakash P , Smadbeck, James , Murphy, Stephen, Mansfield, Aaron S , Murphy, Stephen J. , Borad, Mitesh J. , Baas, Paul, Mansfield, Aaron S.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 7, 2023 | Volume: 11 | Issue: 6 | Pages: e006035

10.1136/jitc-2022-006035 | PMID 37279993 Get It

Background Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden and no robust predictors of survival with ICI. Since ICIs enable adaptive antitumor immune responses, we investigated T-cell receptor (TCR) associations with survival in participants from two clinical trials treated with ICI. Methods We included patients with pleural mesothelioma who were treated with nivolumab (NivoMes, NCT02497508) or nivolumab and ipilimumab (INITIATE, NCT03048474) after first-line therapy. TCR sequencing was performed with the ImmunoSEQ assay in 49 and 39 pretreatment and post-treatment patient peripheral blood mononuclear cell (PBMC) samples. These data were integrated with TCR sequences found in bulk RNAseq data by TRUST4 program in 45 and 35 pretreatment and post-treatment tumor biopsy samples and TCR sequences from over 600 healthy controls. The TCR sequences were clustered into groups of shared antigen specificity using GIANA. Associations of TCR clusters with overall survival were determined by cox proportional hazard analysis. Results We identified 4.2 million and 12 thousand complementarity-determining region 3 (CDR3) sequences from PBMCs and tumors, respectively, in patients treated with ICI. These CDR3 sequences were integrated with 2.1 million publically available CDR3 sequences from healthy controls and clustered. ICI-enhanced T-cell infiltration and expanded T cell diversity in tumors. Cases with TCR clones in the top tertile in the pretreatment tissue or in circulation had significantly better survival than the bottom two tertiles (p<0.04). Furthermore, a high number of shared TCR clones between pretreatment tissue and in circulation was associated with improved survival (p=0.01). To potentially select antitumor clusters, we filtered for clusters that were (1) not found in healthy controls, (2) recurrent in multiple patients with mesothelioma, and (3) more prevalent in post-treatment than pretreatment samples. The detection of two-specific TCR clusters provided significant survival benefit compared with detection of 1 cluster (HR<0.001, p=0.026) or the detection of no TCR clusters (HR=0.10, p=0.002). These two clusters were not found in bulk tissue RNA-seq data and have not been reported in public CDR3 databases. Conclusions We identified two unique TCR clusters that were associated with survival on treatment with ICI in patients with pleural mesothelioma. These clusters may enable approaches for antigen discovery and inform future targets for design of adoptive T cell therapies.
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Paweletz, Cloud P. , Heavey, Grace A. , Kuang, Yanan , Durlacher, Emily , Kheoh, Thian , Chao, Richard C. , Spira, Alexander I. , Leventakos, Konstantinos , Johnson, Melissa L. , Ou, Sai‐Hong Ignatius , Riely, Gregory J. , Anderes, Kenna , Yang, Wenjing , Christensen, James G. , Jänne, Pasi A. , Johnson, Melissa L , Ou, Sai-Hong I

Mayo Clinic

Clinical Cancer Research | June 6, 2023 | Volume: 29 | Issue: 16 | Pages: 3074-3080

10.1158/1078-0432.ccr-23-0795 | PMID 37279096 Get It

Abstract Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here, we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C-mutant lung cancer. Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRAS G12C-mutant patients with lung cancer that participated in cohort A of the KRYSTAL-1 clinical trial. We analyzed the change in ctDNA at 2 specific intervals: Between cycles 1 and 2 and at cycle 4. Changes in ctDNA were compared with clinical and radiographic response. Results: We found that, in general, a maximal response in KRAS G12C ctDNA levels could be observed during the initial approximately 3-week treatment period, well before the first scan at approximately 6 weeks. 35 patients (89.7%) exhibited a decrease in KRAS G12C cfDNA &gt;90% and 33 patients (84.6%) achieved complete clearance by cycle 2. Patients with complete ctDNA clearance at cycle 2 showed an improved objective response rate (ORR) compared with patients with incomplete ctDNA clearance (60.6% vs. 33.3%). Furthermore, complete ctDNA clearance at cycle 4 was associated with an improved overall survival (14.7 vs. 5.4 months) and progression-free survival (HR, 0.3). Conclusions: These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.
Commentary: Daily Pain Prediction Using Smartphone Speech Recordings of Patients With Spine Disease
Bydon, Mohamad , Johnson, Sarah E. , Katsos, Konstantinos, Katsos, Konstantinos D.

Mayo Clinic

Neurosurgery | April 20, 2023 | Volume: 93 | Issue: 3 | Pages: e61-e62

10.1227/neu.0000000000002503 | PMID 37078725 Get It

Current Applications of Machine Learning for Spinal Cord Tumors
Johnson, Sarah E. , Ibrahim, Sufyan , Bydon, Mohamad , Katsos, Konstantinos, Johnson, Sarah E , Ibrahim, Sufyan , Katsos, Konstantinos D.

Mayo Clinic

Life | February 14, 2023 | Volume: 13 | Issue: 2 | Pages: 520

10.3390/life13020520 | PMID 36836877 Get It

Spinal cord tumors constitute a diverse group of rare neoplasms associated with significant mortality and morbidity that pose unique clinical and surgical challenges. Diagnostic accuracy and outcome prediction are critical for informed decision making and can promote personalized medicine and facilitate optimal patient management. Machine learning has the ability to analyze and combine vast amounts of data, allowing the identification of patterns and the establishment of clinical associations, which can ultimately enhance patient care. Although artificial intelligence techniques have been explored in other areas of spine surgery, such as spinal deformity surgery, precise machine learning models for spinal tumors are lagging behind. Current applications of machine learning in spinal cord tumors include algorithms that improve diagnostic precision by predicting genetic, molecular, and histopathological profiles. Furthermore, artificial intelligence-based systems can assist surgeons with preoperative planning and surgical resection, potentially reducing the risk of recurrence and consequently improving clinical outcomes. Machine learning algorithms promote personalized medicine by enabling prognostication and risk stratification based on accurate predictions of treatment response, survival, and postoperative complications. Despite their promising potential, machine learning models require extensive validation processes and quality assessments to ensure safe and effective translation to clinical practice.
Characterization of Genetic Findings Underlying Aggressive B-Cell Lymphomas with Atypical Results on MYC Break-Apart Fluorescence in Situ Hybridization (FISH) Analysis
Gagnon, Marie-France, Penheiter, Alan R. , Johnson, Sarah H. , Smadbeck, James B. , Sadeghian, Dorsay, Harris, Faye R. , Karagouga, Giannoula, McCune, Alexa, Hoppman, Nicole L., Xu, Xinjie , Vasmatzis, George , King, Rebecca L. , Ketterling, Rhett P. , Greipp, Patricia T. , Peterson, Jess F. , Baughn, Linda B.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9272-9273

10.1182/blood-2022-158832 Get It

EXTH-20. IDENTIFICATION OF EX VIVO THERAPEUTIC VULNERABILITIES IN DIFFUSE GLIOMAS USING A FUNCTIONAL GENOMICS APPROACH
Lin, Wan‐Hsin , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan W. , Sadeghian, Dorsay, Johnson, Sarah H. , Karagouga, Giannoula, Harris, Faye R. , Quiñones‐Hinojosa, Alfredo , Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugała, Maciej M. , Rosenfeld, Steven S. , Jentoft, Mark E. , Emanuel, Angela, Schaefer-Klein, Janet, Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Kizilbash, Sani H , Murphy, Stephen J. , Burns, Terry C. , Bendok, Bernard R. , Moniz‐Garcia, Diogo , Ensign, Shannon P. Fortin , Ida, Cristiane M. , Salomao, Marcela , Yang, Lin , Mansfield, Aaron S. , Borad, Mitesh J.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii213-vii214

10.1093/neuonc/noac209.819 Get It

Abstract Diffuse gliomas are aggressive brain tumors that lack effective therapies. Despite advances in the molecular characterization of gliomas, targeted treatments have failed to improve patient outcomes to date. Here, we employed a functional genomics approach to rapidly identify therapeutic vulnerabilities and provide a strategy to individualize patient treatment. Our process combined comprehensive genomic and transcriptomic tumor profiling, custom algorithms and visualization software for data integration, and preclinical 3-dimensional ex vivo models (mcancers) for drug screening to assess response to therapeutic agents targeting specific molecular alterations. A total of 32 cases, including 5 oligodendrogliomas (1 primary and 4 recurrent), 5 astrocytomas (1 primary and 4 recurrent), and 22 glioblastomas (5 primary and 17 recurrent), were included in the study. Immunohistochemistry and integrated genomics confirmed that mcancers maintain key molecular alterations, including mutations, chromosomal rearrangements and focal amplifications, cellularity, and heterogeneity, faithfully recapitulating the original tumor. A total of 119 single drugs and 183 combinations were tested, including a panel of 26-brain penetrant targeted agents (18 single drugs and 8 combinations) that was curated to target common glioma oncogenic pathways and was tested across all cases. A strong correlation was observed between therapeutic vulnerabilities of glioma mcancers to targeted agents (EGFR, MET, PDGFR, HDAC inhibitors, etc.) and clinical experience. Single agent activity of panel compounds in the ex vivo setting was generally poor, with only 35% mCancers exhibiting &gt; 70% growth inhibition at Cmax. In contrast, combination strategies, especially ones including epigenetic drugs, were significantly more effective (affecting 22 out of 32 mCancers), underscoring the molecular complexity of gliomas and the need for clinical trials testing combination treatments. Our data identified a number of novel combination treatments with significant efficacy across glioma subtypes and molecular profiles, suggesting that our functional genomics pipeline can guide treatment selection and inform clinical trial enrollment for gliomas.
660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen
Liao, Chih‐Yi , Henick, Brian S. , Overman, Michael J. , Polite, Blasé N. , Roychowdhury, Sameek , Ahn, Daniel H. , Johnson, Melissa M., Schenk, Desiree, Bae, Kyounghwa, Jooss, Karin , Johnson, Benny , Spira, Alexander I. , Carbone, David Paul , Mahipal, Amit , Johnson, Melissa, Davis, Matthew M. , Ferguson, Andrew, Solomon, Benjamin

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A691-A691

10.1136/jitc-2022-sitc2022.0660 Get It

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Riely, Gregory J. , Heist, Rebecca S. , Pacheco, Jose M., Sabari, Joshua K. , Leventakos, Konstantinos , Yau, Edwin , Zhang, Jun , Velastegui, Karen , Christensen, James G. , Yan, Xiaohong , Anderes, Kenna , Jänne, Pasi A. , Spira, Alexander I. , Gadgeel, Shirish M. , Ou, Sai‐Hong Ignatius , Johnson, Melissa L. , Bazhenova, Lyudmila , Negrao, Marcelo Vailati , Pennell, Nathan A , Chao, Richard C.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9002-9002

10.1200/jco.2022.40.16_suppl.9002 Get It

9002 Background: KRAS is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRASG12C mutation occurs in ̃14% of NSCLC. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib is optimized for favorable pharmacokinetic (PK) properties, including long half-life (̃24 h), dose-dependent PK, and central nervous system penetration; it has demonstrated objective response and favorable tolerability in the Phase 1/1b setting. Methods: KRYSTAL-1 (NCT03785249) is a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combination regimens in patients with advanced solid tumors harboring a KRASG12C mutation. Here we report the first disclosure from all patients enrolled in Cohort A, a Phase 2 cohort with registrational intent, evaluating adagrasib given 600 mg orally BID in patients with NSCLC previously treated with platinum-based chemotherapy and anti-PD-1/L1 therapy. Study objectives include evaluating efficacy (objective response rate [ORR], duration of response [DOR], progression-free survival [PFS], overall survival [OS]), safety, PK, and exploratory correlative analyses. Objective tumor response was assessed per RECIST v1.1 by blinded independent central review (BICR). Results: As of the 15 October 2021 data cutoff, 116 patients with NSCLC harboring a KRASG12C mutation were enrolled and treated, with a median follow-up of 12.5 months. Baseline characteristics include median age 64 years, 65% female, and 15.5%/83.6% with ECOG PS 0/1; 98.3% of patients received adagrasib following prior treatment with immunotherapy and chemotherapy, with a median of 2 prior systemic therapies. The ORR (by BICR) was 42.9% (48/112) and the disease control rate was 79.5% (89/112); 31 patients remain on treatment. Median DOR was 8.5 months (95% CI 6.2–13.8), median PFS was 6.5 months (95% CI 4.7–8.4), median OS was 12.6 months (95% CI 9.2–NE). Treatment-related AEs (TRAEs) of any grade occurred in 97.4% of patients, grade ≥3 TRAEs in 45.7%, 2 grade 5 TRAEs, and 8 (6.9%) TRAEs led to discontinuation. The most commonly reported (≥25%) TRAEs (any grade) were diarrhea (62.9%), nausea (62.1%), vomiting (47.4%), fatigue (40.5%), ALT/AST increased (27.6%/25%), blood creatinine increased (25.9%); the most commonly reported (≥5%) TRAEs (grade 3/4) were lipase increased (6%) and anemia (5.2%). Additional subgroup analyses will be presented, including selected demographics, molecular markers and sites of metastases. Conclusions: Adagrasib is well tolerated and demonstrates promising efficacy in pretreated patients with NSCLC harboring a KRASG12C mutation. A Phase 3 trial evaluating adagrasib monotherapy versus docetaxel in previously treated patients with KRASG12C-mutant NSCLC is ongoing (NCT04685135). Clinical trial information: NCT03785249.
A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm
Dalland, Joanna , Blackburn, Patrick R. , Reichard, Kaaren K. , Johnson, Sarah H. , Smadbeck, James B. , Vasmatzis, George , Hoppman, Nicole L., Xu, Xinjie, Greipp, Patricia T. , Peterson, Jess F. , Dalland, Joanna C , Peterson, Jess F , Greipp, Patricia T , Baughn, Linda B.

Mayo Clinic

Laboratory Medicine | January 27, 2022 | Volume: 53 | Issue: 5 | Pages: e134-e138

10.1093/labmed/lmac010 | PMID 35217871 Get It

Abstract The World Health Organization category of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangements is composed of a heterogeneous group of neoplasms that can present as a myeloproliferative neoplasm, acute myeloid leukemia, myeloid sarcoma, or lymphoblastic leukemia/lymphoma. The overall outcome of these neoplasms is favorable with imatinib therapy. Herein, we describe an adult female patient with a myeloid neoplasm accompanied by eosinophilia and a novel USP25::PDGFRA gene fusion.